Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Apr 5, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating a new approach to treat high-risk prostate cancer. Specifically, it looks at using a type of radiation therapy called moderately hypofractionated boost, combined with pelvic radiation therapy. This method aims to target the prostate more effectively while also treating the surrounding pelvic area. The trial is open to men aged 18 and older who have been diagnosed with localized high-risk prostate cancer. To qualify, participants must have certain conditions, such as a specific cancer stage or a high level of prostate-specific antigen (PSA) in their blood.

If you or a loved one decide to participate, you will receive external beam radiation therapy as part of the study. Additionally, the treating physician may recommend hormone therapy, which is a common part of prostate cancer treatment. The trial is actively recruiting 100 participants, and all potential participants will need to be able to provide informed consent and meet specific health criteria to join. This study aims to improve treatment options for men with high-risk prostate cancer and help researchers understand how well this new radiation approach works.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Age \> 18 years.
• • Able to provide informed consent.
• • Histologic diagnosis of prostate adenocarcinoma.
• • ECOG performance status 0-1.
• • High-risk localized disease by NCCN criteria (\>cT3, Grade group \>4, or PSA \>20 ng/mL) or clinical N1 disease.
• • Clinical M0 by conventional imaging (computed tomography (CT) and bone scan (BS)) and/or molecular imaging (prostate specific membrane antigen (PSMA)- positron emission tomography (PET))
• Exclusion Criteria:
• • Prior pelvic radiotherapy.
• • Contraindications to radiotherapy